Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563599 | 1.00 | KDM4E (0.44) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL29469491 | 0.95 | KDM4E (0.43) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL3716710 | 0.89 | GSK3B (0.48) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL29845506 | 0.89 | GSK3B (0.48) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL28208485 | 0.87 | GSK3B (0.48) | CLK1DYRK1ADYRK1BNOTUM | |
| SCHEMBL3339233 | 0.86 | DRD2 (0.52) | CLK1DYRK1ADYRK1BKCNH2DRD2 | |
| SCHEMBL30534778 | 0.86 | DRD2 (0.52) | CLK1DYRK1ADYRK1BKCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL29836377 | 0.84 | KCNH2 (0.53) | CLK1DYRK1ADYRK1BKCNH2DRD2 | |
| SCHEMBL16659182 | 0.81 | CTNNB1 (0.43) | KDM4EALDH1A1HPGDCLK1DYRK1A | |
| SCHEMBL31432671 | 0.81 | DRD2 (0.51) | KCNH2DRD2DRD1DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240167066-A1 | METHOD FOR PRODUCING DEMETHYLATED COMPOUND | DAICEL CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022202961-A1 | METHOD FOR PRODUCING DEMETHYLATED COMPOUND | 株式会社ダイセル | 2022-09-29 | — | — | WO | disclosed |
| EP-3390394-B1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022023447-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-2852588-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| WO-2017098254-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2417134-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-0150291-B1 | SUBSTITUTED 5-HYDROXY-2,3-DIHYDROBENZOFURANS AND 6-HYDROXY-2,3-DIHYDROBENZOPYRANS AND ANALOGUES THEREOF USEFUL AS ANTI-INFLAMMATORY AGENTS | MERCK & CO. INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| US-4563476-A | TOPICAL, SKIN DISORDERS | MERCK & CO., INC. (US) | 1986-01-07 | — | — | US | disclosed |
| US-4558067-A | Phenylthiomethyl-6-hydroxy-2,3-dihydrobenzo-pyran and analogs thereof useful as anti-inflammatory agents | MERCK & CO., INC. (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0150291-A1 | Substituted 5-hydroxy-2,3-dihydrobenzofurans and 6-hydroxy-2,3-dihydrobenzopyrans and analogues thereof useful as anti-inflammatory agents | MERCK & CO. INC. (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | KDM4E 3609/4885NPC1 427/4885ALDH1A1 1913/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | KDM4E 3609/4885NPC1 427/4885ALDH1A1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.